U.S., July 26 -- ClinicalTrials.gov registry received information related to the study (NCT07085039) titled 'Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease' on May 20.
Brief Summary: The research study is being done to look at the effects of ruxolitinib in adults with idiopathic Multicentric Castleman Disease (iMCD) that has not gotten better from taking siltuximab or tocilizumab, or who cannot take those medications.
Study Start Date: Sept. 01
Study Type: INTERVENTIONAL
Condition:
Castleman's Disease (CD)
Idiopathic Multicentric Castleman's Disease
Intervention:
DRUG: Ruxolitinib
Participants will take the study drug in a tablet form, by mouth, every day for the next year, as long as it is helping w...